Herein are described methods of treating a human subject having acute myeloid leukemia (AML) that is refractory to induction therapy, wherein an MDM2 inhibitor is administered before or concurrently with chemotherapy, which may comprise induction therapy. Refractory AML may be predicted based on decreased expression of MTF2 in cells from a hematological sample obtained from the subject. Also provided are methods of predicting and treating AML responsive to MDM2/HDM2 inhibitors, based on MTF2 expression. One set of additional biomarkers useful in the predictions comprise one or more of H3K27me3, CD84, CD92, MDM2, NPM1, PRICKLE1, SET, ABCB6, POLQ, POLK, POLH, ARTIMIS, MCM6, CD327, CD90 and PARP1. Another set of additional biomarkers useful in the predictions include at least one of H3K27me3, MDM2, NPM1, SET, CD84 and PRICKLE1. Methods of selecting a patient for treatment with an MDM2 inhibitor before or concurrently with chemotherapy are also provided, along with kits and uses.

The present subject matter provides compositions, formulations and methods for preventing or reducing proliferation or migration of retinal cells or epithelial to mesenchymal transition in ocular cells or cells from other tissues.

The current disclosure relates to pharmaceutical combinations and compositions useful in the treatment of certain types of cancer. The disclosure also relates to methods for treatment of these types of cancer. In particular, the disclosure relates to the combined use of of an inhibitor of a protein of the MAPK/ERK pathway and an inhibitor of specific kinases in the treatment of a cancer, in particular melanoma, in a patient. In an important embodiment, the cancer is characterized by the absence or reduced expression of MITF.

The present invention relates to an in vitro method for determine the prognosis of the survival time of a patient suffering from a cancer comprising the steps consisting of i) determining the expression level of the couple DNMT3A/ISGF3γ in a sample from said patient, ii) comparing said expression level with a predetermined reference value and iii) providing a good prognosis when the expression level is lower than the predetermined reference value and a poor prognosis when the expression level is higher than the predetermined reference value. The invention also relates a compound which is a DNMT3A/ISGF3γ antagonist or a compound which is a DNMT3A/ISGF3γ gene expression inhibitor for use in the treatment and prevention of cancer.

The present invention provides markers, marker signatures and molecular targets that correlate with dysfunction of immune cells and are advantageously independent of the immune cell activation status. The present markers, marker signatures and molecular targets provide for new ways to evaluate and modulate immune responses. Specifically, POU2AF1 modulation is provided for use as a marker, marker signature and molecular target. Therapeutic methods are also provided to treat a patient in need thereof who would benefit from an increased immune response.

The present technology provides methods and compositions for identifying and treating cancers by targeting the cytosolic dsDNA sensing pathway (cGAS-STING) in chromosomally unstable cancers. In some embodiments, the present technology also provides methods for detecting chromosomal instability in cancer and treating cancers associated with altered levels of cyclic GMP-AMP synthase (cGAS), stimulator of interferon genes (STING), and/or ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1).

A method of measuring an analyte amount in a whole blood sample, including (i) measuring the haematocrit level of the whole blood sample; (ii) measuring an analyte amount directly in the whole blood sample; and (iii) calculating a corrected analyte amount according to relation D.sub.P=P.sub.a(D.sub.ST, D.sub.H), where D.sub.p, is the corrected analyte amount, D.sub.ST is the measured analyte amount, D.sub.H is the measured haematocrit level, and P.sub.a is a non-constant polynomial of a degree greater than or equal to 1 having as indeterminate values the measured analyte amount, D.sub.ST, and the measured haematocrit level, D.sub.H, and having its polynomial coefficients depending on the analyte.

The present invention provides therapeutic and diagnostic methods and compositions for treating a human metastatic cancer. Specifically, the invention provides methods of treatment and methods for determining whether an individual suffering from a cancer is responding to an AXL decoy protein-based therapy, predicting responsiveness of an individual suffering from a cancer to treatment comprising an AXL decoy protein, and methods of selecting a therapy for an individual suffering from cancer.

The present invention relates to a method for assessing whether a subject shall be subjected to an imaging based diagnostic assessment. The method is based on the determination of the amount(s) of a cardiac Troponin and/or Fibroblast Growth Factor 23 (FGF-23) in a sample from the subject, and on the comparison of the, thus, determined amount(s) with a reference amount (reference amounts). The present invention also relates to a system for performing an assessment whether a subject shall be subjected to an imaging based diagnostic assessment and to reagents and kits used in performing the methods disclosed herein. Moreover, the present invention is directed to a method for predicting the risk of mortality and/or of a cardiovascular event. Also encompassed is a method for diagnosing an early stage of LVH in a subject having a preserved left ventricular ejection.

The present disclosure relates to a group of peptide compounds and their use in identifying molecules that stimulate proteasome or immunoproteasome are disclosed herein. Composition matters and methods of uses are within the scope of this disclosure.